Nurix Therapeutics Reports Strong Phase 1b Data for BTK Degrader Bexobrutideg, Supporting Phase 3 & Roche Collaboration
NRIX has more than doubled off its 52-week low of $8.195.
Summary
Nurix Therapeutics announced updated positive clinical data for its lead BTK degrader, bexobrutideg, showing high response rates and a favorable safety profile in CLL/SLL patients, further validating its potential and supporting advancement to Phase 3.
Key Events · Product Development and Regulatory · NRIX
-
Updated Phase 1a/b Clinical Data
Nurix Therapeutics presented updated positive clinical data for its novel Bruton's tyrosine kinase (BTK) degrader, bexobrutideg (NX-5948), in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
-
High Objective Response Rates
The Phase 1a study in heavily pretreated patients showed an objective response rate (ORR) of 83.0% with a median progression-free survival of 22.1 months. New Phase 1b data in earlier-line cohorts demonstrated ORRs of 92.9% (BTKi-treated, BCL2i-naïve) and 84.2% (BTKi-naïve).
-
Favorable Safety Profile
Bexobrutideg was well tolerated across the Phase 1a/1b population, consistent with prior disclosures, with no dose-limiting toxicities or treatment-related Grade 5 adverse events reported.
-
Supports Phase 3 & Roche Collaboration
The updated data reinforces the potential for a broad Phase 3 monotherapy program and strengthens the rationale for exploring combination regimens, building on the recently announced global collaboration with Roche for bexobrutideg.
Analysis · NRIX · Life Sciences
This filing provides updated positive clinical data for Nurix's lead BTK degrader, bexobrutideg, which is critical as it directly validates the asset that recently secured a major global collaboration with Roche. The strong efficacy and safety profile in both heavily pretreated and earlier-line CLL/SLL patients significantly de-risks the drug's development and strengthens the rationale for advancing to a broad Phase 3 program. This positive data reinforces the investment thesis by demonstrating the drug's potential as a best-in-class therapy, crucial for a clinical-stage biopharmaceutical company.
At the time of this filing, NRIX was trading at $16.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $8.20 to $22.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.